Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial

What Was Tested

This randomized controlled trial paper looks at Triptorelin in the context of pregnancy and breastfeeding: safety notes.

To evaluate long-term results of LHRHa-induced ovarian suppression during breast cancer chemotherapy.

Why It Was Studied

Whether the administration of luteinizing hormone-releasing hormone analogues (LHRHa) during chemotherapy is a reliable strategy to preserve ovarian function is controversial owing to both the lack of data on long-term ovarian function and pregnancies and the safety concerns about the potential negative interactions between endocrine therapy and chemotherapy.

Who Took Part

The study group was 2008, women.

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

Between October 2003 and January 2008, 281 premenopausal women with stage I to III hormone receptor-positive or hormone receptor-negative breast cancer were enrolled.

Patients were randomized to receive adjuvant or neoadjuvant chemotherapy alone (control group) or chemotherapy plus triptorelin (LHRHa group).

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Triptorelin study: the women and staff both knew the treatment.

The Triptorelin group and the comparison group ran side by side rather than switching.

Last annual follow-up was June 3, 2014.

What Was Measured

PubMed files the paper under topics including Antineoplastic Agents, Hormonal, Breast Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Drug Interactions, Luteolytic Agents and Menstrual Cycle.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Triptorelin in 2008, women in people with pregnancy and breastfeeding: safety notes.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (JAMA), a journal based in United States.

More context: the Triptorelin compound page, Pregnancy and breastfeeding: safety notes research.